Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. - Wikidata - awgldk - TriplyDB

Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.

Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.

http://www.wikidata.org/entity/Q35065775

about

Antibiotic therapy of pneumonia in the obese patient: dosing and delivery Dosing of antibacterial agents in obese adults: does one size fit all?Obesity and the risk and outcome of infection.Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns.Drug disposition in pathophysiological conditions.Antibiotic dosing in obesity: the search for optimum dosing strategies.Comprehensive Guidance for Antibiotic Dosing in Obese Adults.Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization.Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.Population Pharmacokinetics of Levofloxacin in Plasma and Bone of Patients Undergoing Hip or Knee Surgery.

P2860

Q29248400-0E3A9F4E-0072-4A64-B107-E4AC743C3683 Q30362353-5F0FBF8B-D60E-417D-BDA0-1509B80BD9B7 Q30416191-EE7AA1F1-CCBC-4465-BA12-5D5F9264E225 Q37678156-A59EE989-D0BC-4441-BFC6-E9F1BA9657A1 Q38022659-53DBF0C9-22BF-4390-89CC-88D5295C421F Q38397264-748B66BB-8B93-4B46-B2D7-C62A7041FD7D Q40067964-C94ECE19-FB71-4528-9BC3-7250D8F08212 Q42042948-ECE6548E-04EE-40D3-B444-051E908C1B89 Q44455948-E3D19D3D-1510-419F-BC7B-68B3B08B805A Q47291793-A3F093F4-5F85-4BF7-885E-A8E92B146520

P2860

Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.

http://www.wikidata.org/entity/Q35065775

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pharmacokinetics of intravenou ...... 50 milligrams in obese adults.

@ast

Pharmacokinetics of intravenou ...... 50 milligrams in obese adults.

@en

type

label

Pharmacokinetics of intravenou ...... 50 milligrams in obese adults.

@ast

Pharmacokinetics of intravenou ...... 50 milligrams in obese adults.

@en

prefLabel

Pharmacokinetics of intravenou ...... 50 milligrams in obese adults.

@ast

Pharmacokinetics of intravenou ...... 50 milligrams in obese adults.

@en

P1433

Q35065775-A42C73C1-0F07-4594-92DD-8A203B43EB34

P1476

Q35065775-7C3BA204-CF83-4C19-84BB-5CBDE515D1D9

P2093

Q35065775-02D64727-D9A4-4F05-AEAE-0236828860CB

Q35065775-3DF6753E-0693-4466-A2BE-1FAFE3644F06

Q35065775-7D69B9FA-4DEF-4983-9B1B-BCEBE4FD8E57

Q35065775-CA0FA062-16BD-4DE3-9EB3-A66889BAB2A2

P2860

Q35065775-05F67E4A-327D-4AD1-BC69-1FBCC2A66CE7

Q35065775-15DA0186-62C1-412A-A6BD-5A91E60F9E07

Q35065775-3F432DC8-5AB6-4BD6-BCC5-9FAE485C85DB

Q35065775-45378E0C-94A9-4837-90CC-AE037A284F30

Q35065775-4DD8E57C-E740-4E31-A4A1-29D2B993788A

Q35065775-5705C307-5EDB-465F-806D-1E4EA09C1DEF

Q35065775-5B739944-456F-4A82-8911-852F936E5CEA

Q35065775-70BD99E2-61AF-4CF3-BEB7-3502BE917B5E

Q35065775-7684F15C-8A44-4B67-A0FB-009FAEC8FC5B

Q35065775-7B65D907-EA25-4DD5-AE99-8FA2971B1629

P304

Q35065775-CF235B6B-D7C5-41FD-8D49-0C926A0AE3C1

P31

Q35065775-65FB4D82-3F85-46BA-922D-7B7E2FCC386B

P356

Q35065775-0F77FB2A-A9C1-4B6C-AEBF-3EA03B49C44F

P407

Q35065775-41F223A9-5A7D-4979-A751-EE243EB4976B

P433

Q35065775-F6E21EC9-04B8-4599-82B3-F399D31FAFFE

P478

Q35065775-F9542DD9-90C2-4802-9C2E-B09570F7B25D

P577

Q35065775-0D5C3152-B713-48E1-9CD4-552CD25F7CAD

P698

Q35065775-E7685F9B-6415-475C-A068-B3344CFD9A84

P921

Q35065775-C293DF8F-D946-417F-9000-62258B17DEEC

P932

Q35065775-65053D3D-F527-4C1F-8208-CF135D7FADE6

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics of intravenou ...... 50 milligrams in obese adults.

@en

P2093

Aaron M Cook

http://www.w3.org/2001/XMLSchema#string

Craig Martin

http://www.w3.org/2001/XMLSchema#string

R Scott Morehead

http://www.w3.org/2001/XMLSchema#string

Val R Adams

http://www.w3.org/2001/XMLSchema#string

P2860

Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.

Pharmacokinetics of antibiotics in burn patients.

Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients

Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects.

Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

Pharmacokinetic alterations after severe head injury. Clinical relevance.

Pharmacokinetics of drugs used in critically ill adults.

P304

3240-3243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01680-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21576432

http://www.w3.org/2001/XMLSchema#string

P921

P932

3122410

http://www.w3.org/2001/XMLSchema#string